
1. med j aust. 2016 apr 18;204(7):268-72.

australian recommendations management hepatitis c virus infection: a
consensus statement.

thompson aj(1).

author information: 
(1)department gastroenterology, st vincent's hospital, melbourne, vic
alexander.thompson@svha.org.au.

chronic hepatitis c virus (hcv) infection affects 230 000 australians, at
risk progressive liver fibrosis leading cirrhosis, liver failure and
hepatocellular carcinoma. hcv infection curable, australians living
with hcv considered antiviral therapy. interferon-free regimens
involving combinations sofosbuvir, ledipasvir, daclatasvir and/or ribavirin
for 8, 12 24 weeks listed pharmaceutical benefits scheme (pbs) 
for treating people genotypes 1-3 hcv. treatment genotypes 4-6 hcv
involves sofosbuvir plus peginterferon-alfa ribavirin 12 weeks. pbs
listing allows therapies prescribed specialists experienced in
treating chronic hcv infection general practitioners consultation with
one specialists. people cirrhosis special populations
(eg, decompensated liver disease renal impairment) be
referred specialist care. key issues pre-treatment assessment include 
identifying hcv genotype, evaluating cirrhosis considering concomitant
medications risk drug-drug interactions.

doi: 10.5694/mja16.00106 
pmid: 27078601  [indexed medline]

